Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery

• Published in: Cancers 2023-11, Vol.15 (22), p.5478
• Main Authors: Sazdova, Iliyana, Keremidarska-Markova, Milena, Dimitrova, Daniela, Mitrokhin, Vadim, Kamkin, Andre, Hadzi-Petrushev, Nikola, Bogdanov, Jane, Schubert, Rudolf, Gagov, Hristo, Avtanski, Dimiter, Mladenov, Mitko
• Format: Article
• Language: English
• Subjects: Antioxidants; Antitumor agents; Apoptosis; Bioavailability; Cancer; Cancer therapies; Cell cycle; Chemotherapy; Colon cancer; Curcumin; Cytokines; Development and progression; Drug delivery; Drug delivery systems; Drug therapy; Drugs; Enzymes; Health aspects; Inflammation; Lipids; miRNA; NF-κB protein; Oxidative stress; Pancreatic cancer; Pharmacokinetics; Physiological aspects; Prevention; Prostate cancer; Proteasomes; Proteins; Tumor necrosis factor-TNF; Tumors; Vehicles
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15225478

EF24, a synthetic monocarbonyl analog of curcumin, shows significant potential as an anticancer agent with both chemopreventive and chemotherapeutic properties. It exhibits rapid absorption, extensive tissue distribution, and efficient metabolism, ensuring optimal bioavailability and sustained exposure of the target tissues. The ability of EF24 to penetrate biological barriers and accumulate at tumor sites makes it advantageous for effective cancer treatment. Studies have demonstrated EF24’s remarkable efficacy against various cancers, including breast, lung, prostate, colon, and pancreatic cancer. The unique mechanism of action of EF24 involves modulation of the nuclear factor-kappa B (NF-κB) and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, disrupting cancer-promoting inflammation and oxidative stress. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through inhibiting the NF-κB pathway and by regulating key genes by modulating microRNA (miRNA) expression or the proteasomal pathway. In summary, EF24 is a promising anticancer compound with a unique mechanism of action that makes it effective against various cancers. Its ability to enhance the effects of conventional therapies, coupled with improvements in drug delivery systems, could make it a valuable asset in cancer treatment. However, addressing its solubility and stability challenges will be crucial for its successful clinical application.